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Abstract
Objective: Uterine carcinosarcoma is a rare, aggressive sub-
type of endometrial cancer. Treatment consists of hysterec-
tomy, bilateral salpingo-oophorectomy, and lymphadenec-
tomy (LND). The survival benefit of LND in relation to adju-
vant radio- and/or chemotherapy is unclear. We evaluated 
the impact of LND on survival in relation to adjuvant therapy 
in uterine carcinosarcoma. Methods: Retrospective data on 
1,140 cases were combined from the Netherlands Cancer 
Registry (NCR) and the nationwide network and registry of 
histo- and cytopathology in the Netherlands (PALGA). LND 
was defined as the removal of any nodes. Additionally, cases 
where 10 nodes or less (LND ≤10) or more than 10 nodes 
(LND > 10) were removed were analyzed separately. Adju-
vant therapy was evaluated as radiotherapy, chemotherapy, 
or radiochemotherapy. Associations were analyzed by χ2 
test, log-rank test, and Cox regression analysis. Results: 
Overall survival (OS) had improved after total abdominal 
hysterectomy with bilateral salpingo-oophorectomy with 
LND > 10 (HR 0.62, 95% CI 0.47–0.83). Adjuvant therapy was 
related to OS with an HR of 0.64 (95% CI 0.54–0.75) for radio-
therapy, an HR of 0.65 (95% CI 0.48–0.88) for chemotherapy, 
and an HR of 0.25 (95% CI 0.13–0.46) for radiochemotherapy. 
Additionally, adjuvant treatment was related to OS when 
lymph nodes were positive (HR 0.22, 95% CI 0.11–0.42), but 
not when they were negative. Conclusion: LND is related to 
improved survival when more than 10 nodes are removed. 
Adjuvant therapy improves survival when LND is omitted, or 
when nodes are positive. © 2018 S. Karger AG, Basel
Introduction
Uterine carcinosarcoma (UCS) is a rare and aggressive 
histological subtype of endometrial cancer. The incidence 
is approximately 5 cases per 1,000,000 person-years, and 
5-year survival is between 32 and 39% [1–4]. Primary 
treatment consists of a total abdominal hysterectomy 
with bilateral salpingo-oophorectomy (TAH-BSO) and 
lymphadenectomy (LND).
LND as a treatment tool is still under debate [4–6]. 
Some relatively small studies describe no benefit of LND 



















   
   
   
   
   
   
   
   
   

























an improved survival of patients on whom LND was per-
formed [2, 9, 10]. This is in accordance with studies on 
other aggressive subtypes of endometrial cancer like 
high-grade endometrial and serous endometrial cancer. 
Two of these studies evaluated the number of nodes that 
were removed in relation to survival, as it seems plausible 
that there may not be an optimal treatment effect when 
only a few nodes are removed. Nemani et al. [2] found no 
significant difference between removal of more than 12 
and less than 12 nodes. Conversely, Temkin et al. [9] 
found survival to be improved when more than 11 nodes 
are removed.
A limitation of the studies mentioned above is that 
their findings were not corrected for adjuvant radio- and/
or chemotherapy (CT) [2, 9, 10]. This may have influ-
enced the findings, as adjuvant radiotherapy (RT), CT, 
and combined radiochemotherapy (RCT) may improve 
the survival of UCS patients [11–14]. It is therefore un-
known how LND, RT, and CT together are related to sur-
vival with UCS.
The aim of this study was to evaluate the role of LND 
with or without RT and/or CT in a large retrospective co-
hort of 1,140 patients diagnosed with UCS undergoing 
primary surgery with a curative intent.
Subjects and Methods
Data Collection and Study Population
Retrospective data were obtained from the Netherlands Cancer 
Registry (NCR) and the nationwide network and registry of histo- 
and cytopathology in the Netherlands (PALGA) [15]. The NCR 
contains data on all newly diagnosed cancers, including patient, 
tumor, and treatment characteristics. Data from the NCR were 
combined with data from PALGA by a coding system connecting 
the two databases. The data were delivered in password-protected 
sets not traceable to individual persons. According to Dutch law, 
no further ethical approval is required. Patients with UCS were 
included between January 1, 1993, and December 31, 2012. Fol-
low-up was completed on December 31, 2013. Included were pa-
tients diagnosed with uterine carcinoma as identified by corre-
sponding ICD-O-3 codes (C54; C55 combined with morphologi-
cal code 8950, 8951, or 8980). In total, 1,310 patients were identified 
to be diagnosed with UCS according to the NCR. However, 170 
patients did not undergo primary surgery defined as TAH-BSO 
with or without LND, leaving 1,140 patients available for further 
analysis.
Data Processing
Both sources, the NCR and PALGA, were combined into one 
database. Inconsistencies between PALGA and the NCR were re-
solved using PALGA as the reference, since this data set most ac-
curately reflects the pathology report. An exception was made for 
disease stage, as the pathology review lacked information on lymph 
node status when LND was omitted. Therefore, disease stage was 
classified according to the FIGO 2009 classification and based on 
the NCR. Distant metastasis was defined as distant metastasis in-
cluding intra-abdominal metastasis, to be described at the time of 
UCS-related surgery. Recurrence of disease after surgery needed 
to be confirmed by histology. LND was defined as the removal of 
any number of nodes. To further evaluate the relevance of the 
number of nodes removed, a distinction was made between re-
moval of 10 lymph nodes or less (LND ≤10) and removal of 11 
nodes or more (LND > 10). Adjuvant treatment was documented 
as RT, CT, or RCT. There was no information as to the timing of 
adjuvant treatment with respect to other treatment. Age at diagno-
sis was divided into 70 years and below and 71 years and above, in 
line with previous publications [1–4].
Table 1. Clinicopathological characteristics of the 1,140 patients 
















































































Values are presented as n (%). Percentages were calculated 
without missing values. TAH-BSO, total abdominal hysterectomy 
with bilateral salpingo-oophorectomy; LND, lymphadenectomy 
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For descriptive statistics, the median and interquartile range 
(IQR) are given where appropriate. Overall survival (OS) was de-
fined as the time until death, with a maximum of 5 years. Disease-
free survival (DFS) was defined as the time until recurrence or 
death, with a maximum of 5 years. The chronological order of 
events for the patients started with surgery, followed by a pathol-
ogy review and possibly adjuvant treatment. Therefore, we first 
analyzed the value of LND, followed by an analysis of all three types 
of adjuvant treatment (RT, CT, and RCT). Finally, we evaluated 
the value of adjuvant treatment in relation to lymph node status 
for cases where LND was performed. FIGO stage, presence of me-
tastasis, myometrial invasion, and age were included in a multi-
variable analysis. To minimize the chance of bias, clinicopatho-
logical variables with more than 10% missing values, such as lym-
phovascular space invasion, were excluded from the survival 
analysis. The statistical analysis was performed with SPSS 22 (IBM, 
Chicago, IL, USA). Relations between variables were tested by χ2 
testing; the log-rank test and Cox regression analysis were used for 




The median age at diagnosis was 70 years (IQR 62–77). 
The clinicopathological characteristics are shown in Ta-
ble 1. The majority (64%) of the patients was diagnosed 
with early-stage disease (FIGO stage 1–2). In 247 patients 
(21.7%), lymph nodes were removed in addition to a 
TAH-BSO. The median number of nodes removed was 
12 (IQR 3–18; data not shown). LND was related to high-
er FIGO stage and age below 70 years (p < 0.001). In 75 of 
the 247 cases, the nodes were positive. When comparing 
LND ≤10 with LND > 10, the percentage of positive nodes 
was not significantly higher when fewer nodes were re-
moved (35 vs. 25%, p = 0.106). Patients from whom lymph 
nodes were removed more often received adjuvant treat-
ment (p < 0.001).

















































































































Values are presented as n (%). Percentages were calculated without missing values. RT, radiotherapy; CT, 



















   
   
   
   
   
   
   
   
   

























Table 2 shows the clinicopathological characteristics 
stratified by adjuvant treatment. Of 622 patients that re-
ceived adjuvant treatment, 77.8% received RT, 16.7% re-
ceived CT, and 5.5% received RCT. RT consisted of exter-
nal beam RT in 90.1% of the cases. Adjuvant treatment 
was related to age above 70 years, increased FIGO stage, 
myometrial invasion, lymph node status, metastasis, and 
lymphovascular space involvement.
Survival Analysis
In the complete cohort of 1,140 patients, median OS 
was 2.03 years (95% CI 1.76–2.30) and median DFS was 
1.53 years (95% CI 1.32–1.76). Histologically proven re-
currence was present in 302 cases (26.5%). Distant recur-
rence was more common than pelvic or local recurrence 
(55.6 vs. 10.9 and 32.1%, respectively, p < 0.01; data not 
shown). Frequency and location of recurrence were not 
related to FIGO stage or age (p > 0.05).
Figure 1 provides a general overview of the distribu-
tion of the various treatment modalities next to median 
OS per subgroup. As expected, median OS was better in 
cases where lymph nodes were removed and turned out 
negative. In this group, there was no difference in median 
OS between patients who did and those who did not re-
ceive adjuvant treatment (4.15 years [95% CI 2.83–6.20] 
and 5.00 years [95% CI 4.49–5.51], respectively). When 
nodes were positive, median OS was much shorter, with 
0.60 years (95% CI 0.09–1.10) for patients who did not 
receive adjuvant treatment and 2.37 years (95% CI 1.52–
3.12) for patients who did receive adjuvant treatment. 
Median OS for patients with surgery limited to TAH-BSO 
was also shorter, with 1.36 years (95% CI 1.04–1.68) for 
patients without adjuvant treatment and 2.01 years (95% 
CI 1.74–2.46) for patients with adjuvant treatment. On-
line supplementary Figure 1 (for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000488531) shows 
similar results for median DFS, with a significant effect of 
adjuvant treatment in cases where no nodes were re-
moved or the nodes turned out to be positive.
Univariate Survival Analysis
Figure 2 shows Kaplan-Meier curves for OS according 
to the extent of surgery and adjuvant treatment. LND was 
related to improved OS (log-rank p < 0.001; Fig. 2a). Fig-
ure 2b shows survival according to the extent of surgery 
with a distinction between LND ≤10 and LND > 10. Sur-
vival with TAH-BSO and LND ≤10 was similar to sur-
vival with TAH-BSO without LND. LND > 10 was related 
to improved survival. Since a cutoff of 10 nodes is arbi-
trary, we also analyzed OS for different cutoff values (re-
moval of 8 or 12 nodes) and found similar results (data 
not shown).
Figure 2c zooms in on 893 cases where surgery was 
limited to TAH-BSO and illustrates an advantage of ad-
juvant treatment in this subgroup (p < 0.001). In univari-
ate Cox regression analysis, RT and RCT but not CT were 
UCS (n = 1,140)
TAH-BSO and removal






























Fig. 1. Median overall survival (OS) (95% CI) in years for the 1,140 patients with uterine carcinosarcoma (UCS) 
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Fig. 2. Kaplan-Meier curves for overall survival (OS) according to 
treatment. a OS and extent of surgery (total abdominal hysterec-
tomy with bilateral salpingo-oophorectomy [TAH-BSO] vs. TAH-
BSO with lymph node dissection [LND]) (n = 1,140). b OS and 
extent of surgery (TAH-BSO vs. TAH-BSO and removal of 10 
nodes or less [LND ≤10] or removal of more than 10 nodes [LND 
> 10]) (n = 1,140). c OS and adjuvant treatment for surgery limited 
to TAH-BSO (n = 893). d OS and adjuvant therapy for patients 
with LND, nodes positive (n = 75). e OS and adjuvant treatment 
































































































































   
   
   
   
   
   
   
   
   

























related to improved OS (HR 0.64 [95% CI 0.55–0.75], HR 
0.32 [95% CI 0.18–0.57], and HR 1.20 [95% CI 0.95–1.52], 
respectively, p < 0.001). On the other hand, when LND 
was performed and the nodes were positive, adjuvant 
treatment was also related to improved survival (log-rank 
p < 0.001; Fig. 2d). In the cases where the nodes were neg-
ative, there was no relation between adjuvant treatment 
and survival.
Of the clinicopathological variables with less than 10% 
missing values, lower FIGO stage (HR 1.47, 95% CI 1.39–
1.57), less myometrial invasion (HR 1.86, 95% CI 1.69–
2.16), no distant metastasis (HR 2.69, 95% CI 2.19–3.31), 
and age below 70 years (HR 2.16, 95% CI 1.59–2.11) were 
related to improved OS.
Multivariable Analysis
Table 3 shows the results of the multivariable analysis 
of OS for the 1,140 patients who received TAH-BSO with 
or without LND. Corrected for adjuvant therapy, FIGO 
stage, age below/above 70 years, myometrial invasion, 
and distant metastasis, LND > 10 was an independent pre-
dictor of OS (HR 0.65, 95% CI 0.48–0.87). LND ≤10 was 
not related to OS (HR 0.83, 95% CI 0.65–1.05). Adjuvant 
therapy was also related to improved OS. RT and CT had 
similar HRs of 0.64 (95% CI 0.54–0.75) and 0.65 (95% CI 
0.48–0.88), respectively. RCT had an HR of 0.25 (95% CI 
0.13–0.46). The results were similar for DFS, with LND > 
10 and adjuvant treatment related to improved DFS (data 
not shown).
Table 4 shows the subgroup analyses stratified 
by lymph node status. In accordance with the findings 
from the univariate analysis, adjuvant treatment was 
not related to OS when the nodes were negative. 
However, when the nodes were positive, adjuvant treat-
ment was related to improved OS, with an HR of 0.17 
(95% CI 0.07–0.39) for RT, an HR of 0.40 (95% CI 0.19–
0.84) for CT, and an HR of 0.04 (95% CI 0.03–0.18) for 
RCT.
Discussion
In this large cohort study, LND was related to im-
proved survival specifically in those cases where more 
than 10 nodes were removed. Adjuvant therapy improves 
survival when LND is omitted, with a similar effect for RT 
and CT. Possibly, the combination of RCT had a cumula-
tive effect. When LND was performed, adjuvant treat-
ment was related to improved survival when the nodes 
were positive but not when they were negative.
The finding that removal of lymph nodes improves 
survival is in accordance with previous publications [2, 5, 
6, 10]. In the largest study, Nemani et al. [2] evaluated the 
role of lymph node dissection in 1,855 patients with stage 
I–III UCS using data from the Surveillance, Epidemiol-
ogy, and End Results (SEER) program in the USA. In the 
57% of cases where lymph nodes were removed, OS was 
improved. However, there was no relation between the 
number of nodes removed and survival when a cutoff of 
12 nodes was used. This is different from our findings, 
since we describe different outcomes for LND ≤10 and 
LND > 10. This may be due to case selection, as lymph 
nodes were removed in fewer cases (22%) in our cohort. 
In our cohort, the nodes were positive in 30% of the cases, 
whereas they were positive in only 14% in the SEER co-
hort. Temkin et al. [9] described 47 cases of UCS where 
at least 1 node was removed, and they also found im-
proved survival in cases where more than 11 nodes were 
Table 3. Multivariable Cox regression analysis of overall survival 
according to extent of surgery, adjuvant therapy, and clinicopath-
ological variables (n = 1,140)
HR (95% CI) p value
Extent of surgery
TAH-BSO
TAH-BSO and LND ≤10













































TAH-BSO, total abdominal hysterectomy with bilateral salpin-
go-oophorectomy; LND ≤10, lymph node dissection of 10 nodes 
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removed. The improved survival in the LND > 10 sub-
group could be explained by a higher probability of re-
moval of all metastatic nodes when more than 10 nodes 
are removed. Another explanation could be that these pa-
tients are cared for by more specialized surgeons or can-
cer centers.
When LND is performed, adjuvant treatment may im-
prove survival when the nodes are positive but not when 
the nodes are negative. Apparently, cases with positive 
nodes are at an increased risk of recurrence despite LND. 
This finding corresponds to the recent findings of the 
PORTEC-3 trial, which investigated the benefit of adju-
vant treatment for other histologic types of high-risk en-
dometrial cancer [16]. A clinical consequence could be to 
omit adjuvant treatment when nodes are negative. Prefer-
ably, these findings should be confirmed in a randomized 
trial of adjuvant treatment for UCS. Nonetheless, it is an 
argument in favor of LND for staging purposes at this 
point. As to the type of adjuvant treatment, Wright et al. 
[12] evaluated adjuvant RT in 1,819 patients with early-
stage UCS also from the SEER database. In accordance 
with our findings, adjuvant RT improved OS, but only in 
cases where LND had been omitted. In another study in-
cluding 2,461 cases from the SEER database, adjuvant 
treatment was related to improved survival for patients 
with advanced disease [11]. This may be because of lymph 
node metastasis in advanced disease, since we found im-
proved survival among patients with positive nodes. The 
relation remained significant in a multivariate analysis 
including FIGO stage.
A few small studies have described a possible survival 
advantage with adjuvant CT similar to that with RT. In a 
small retrospective study on 111 patients with early-stage 
UCS, CT was related to improved survival [13]. Survival 
was similar with CT and RT and further improved with 
RCT. In an even smaller sample of 49 cases, RCT had a 
positive effect on survival, similar to that of RT alone [17]. 
In our large retrospective cohort, we also found a surviv-
al advantage for CT when LND was omitted or the nodes 
were positive. The HRs for CT and RT are within a simi-
lar range, in accordance with a randomized study com-
paring adjuvant RT with CT [18]. That study randomized 
Table 4. Multivariable Cox regression analysis of overall survival after TAH-BSO plus LND stratified by lymph 
node status (n = 273)
TAH-BSO + LND, nodes negative
(n = 129)
TAH-BSO + LND, nodes positive
(n = 75)

























































TAH-BSO, total abdominal hysterectomy with bilateral salpingo-oophorectomy; LND, lymphadenectomy 



















   
   
   
   
   
   
   
   
   

























232 patients with stage I–IV UCS and found no signifi-
cant difference in survival.
As with other retrospective studies, our study has lim-
itations related to the study design. For example, 25.1% of 
the patients who received LND had FIGO stage IIIc can-
cer compared to 1.1% of the patients without LND (p < 
0.001). Likely, this is because of upstaging of patients who 
received LND, which complicates the comparison of 
these two groups. Additionally, the relationship between 
adjuvant treatment and survival in this cohort is similar 
for RT and CT. However, the patient characteristics of 
these two groups are different. For example, the type of 
adjuvant therapy was related to FIGO stage (Table 2). Pa-
tients presenting with early-stage disease more often re-
ceived RT, whereas CT was more common for patients 
presenting with advanced-stage disease. Another issue is 
the cutoff value of 10 nodes to differentiate between 
lymph node sampling and debulking. Assuming that 
LND improves outcome, it is likely that this effect is re-
lated to the number of nodes removed. We set the cutoff 
at 10 nodes, but we are aware that this is arbitrary. As 
mentioned above, we found a similar relation to survival 
when using a cutoff of 8 or 12 nodes.
A strength of this study is the use of a large cohort of 
patients, including information on both RT and CT. In 
addition, the use of two national registries as a source of 
our data improves the reliability of these data.
In conclusion, we describe a survival advantage for 
LND in patients with UCS. In our cohort, the survival 
benefit was limited to cases where more than 10 nodes 
were removed (LND > 10). Adjuvant therapy improved 
survival when surgery was limited to TAH-BSO. When 
LND was performed, the effect of adjuvant treatment was 
limited, although adjuvant treatment was related to im-
proved survival when the nodes were positive. Consider-
ing the type of adjuvant therapy, survival with RT and CT 
was similar, whereas RCT may have further improved 
survival. Our findings can be used in counseling of pa-
tients with newly diagnosed UCS, for whom LND can 
improve survival, especially when more than 10 nodes are 
removed. It remains unclear whether adjuvant treatment 
improves survival when the lymph nodes are negative. 
When the nodes are positive, adjuvant treatment is likely 
to further improve survival.
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